Selecta Biosciences - SELB Stock Forecast, Price & News

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Selecta Biosciences Price Performance

NASDAQ:SELB traded up $0.13 during trading hours on Monday, hitting $2.59. The company had a trading volume of 1,633,345 shares, compared to its average volume of 1,627,036. Selecta Biosciences has a 52 week low of $0.65 and a 52 week high of $4.70. The firm has a 50 day simple moving average of $1.56 and a 200 day simple moving average of $1.43. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.11 and a current ratio of 5.11. The firm has a market capitalization of $395.53 million, a price-to-earnings ratio of 246.00 and a beta of 1.04.

Selecta Biosciences (NASDAQ:SELB - Get Rating) last issued its earnings results on Thursday, August 4th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.09. Selecta Biosciences had a return on equity of 11.30% and a net margin of 24.85%. During the same period in the prior year, the company posted ($0.04) earnings per share. Equities research analysts expect that Selecta Biosciences will post 0.18 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SELB. HC Wainwright decreased their target price on Selecta Biosciences from $6.00 to $4.00 and set a "buy" rating for the company in a research report on Tuesday, June 21st. SVB Leerink initiated coverage on Selecta Biosciences in a research report on Monday, June 6th. They set an "outperform" rating and a $7.00 target price for the company. Needham & Company LLC decreased their price objective on Selecta Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, June 14th. StockNews.com lowered Selecta Biosciences from a "buy" rating to a "hold" rating in a report on Saturday, May 14th. Finally, TheStreet raised Selecta Biosciences from a "d" rating to a "c-" rating in a report on Wednesday, May 25th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $5.33.

Insiders Place Their Bets

In related news, Director Carrie Smith Cox bought 130,000 shares of the business's stock in a transaction on Monday, June 13th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $149,500.00. Following the purchase, the director now directly owns 212,881 shares in the company, valued at $244,813.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 30.50% of the stock is owned by corporate insiders.